Introduction
Androgen signaling via the androgen receptor (AR) is critical for the development of both normal prostate and prostate cancer. In normal prostate development, androgen signaling plays mainly a differentiative role, whereas in prostate cancer the role switches to a proproliferative one (reviewed in Jenster, 1999) . This molecular switch makes the growth of prostate cancer cells dependent on androgens and AR (reviewed in Jenster, 1999; Arnold and Isaacs, 2002) . Indeed, there is increasing evidence that not only prostate cancer initiation but also its progression to the lethal androgen-independent and metastatic form are all dependent on androgens and AR (Isaacs, 1999; Arnold and Isaacs, 2002) . It was recently reported that AR overexpression converts prostate cancer from androgen-sensitive to androgen-insensitive (Chen et al., 2005) . This is further supported by previous findings that functional AR is found in most prostate cancer cells, including late-stage cells that become androgen-independent (Culig et al., 2000) , suggesting that the AR pathway may function throughout prostate carcinogenesis. AR mutations are frequent in prostate cancer, which often broaden AR ligand specificity and convert AR antagonists to agonists (reviewed in Linja and Visakorpi, 2004) . Significantly, a recent study demonstrated that mutation of the AR is sufficient for initiation and progression of prostate cancer in transgenic mice (Han et al., 2005) .
Like other nuclear receptors, the AR is a modular protein consisting of functionally distinct and conserved domains. The amino-terminal region contains transcriptional activation function-1 (AF-1) and the carboxyterminal E region, which harbors the ligand-binding domain (LBD), has activation function-2 (AF-2) that is conserved in other receptors (Durand et al., 1994) . AR transcriptional activity depends on the functions of its two AFs, which are targets of the concerted actions of cofactors. Cofactors can either inhibit (co-repressors or repressors) or enhance (coactivators) AR activity (reviewed in Acevedo and Kraus, 2004) . We have previously published that c-Fos (Tillman et al., 1998) and p53 (Shenk et al., 2001) can disrupt the amino-tocarboxy terminal (N-to-C) interaction of AR. This interaction, which may be intermolecular or intramolecular, is thought responsible for forming a transcriptional competent AR dimer (Langley et al., 1998) . Interestingly, the dimerization of AR, like other nuclear receptors, is driven by the D box in the second zincfinger of the DNA-binding domain (Haelens et al., 2003) . Other AR repressors include histone deacetylase 1 (HDAC1) (Korkmaz et al., 2004) , Hey1 (Belandia et al., 2005) , PIASg (Gross et al., 2004) , silencing mediator for retinoic acid and thyroid hormone receptor (SMRT) (Dotzlaw et al., 2002) , and HBO1 (Sharma et al., 2000) . AR coactivators include SRC-1 (Onate et al., 1998) , TIF2 (Berrevoets et al., 1998) , SRC-3 (also known as RAC3 or AIB1) (Zhou et al., 2005) , and CBP (Aarnisalo et al., 1998) , all of which are overexpressed in prostate cancer (Culig et al., 2004) . Interestingly, SRC-1 (Spencer et al., 1997) and CBP (Martinez-Balbas et al., 1998) have histone acetylase activity. The coactivator p300 is implicated in ligand-independent AR activation (Debes et al., 2002) . SUMO-3 can enhance AR transcriptional activity independent of its sumoylation activity (Zheng et al., 2006) . LSD1 is a histone demethylase that recently was shown to act on the AR and be overexpressed in prostate cancer (Metzger et al., 2005) .
The AR is unique in its interaction with c-Jun, a proto-oncoprotein that can heterodimerize with c-Fos to form AP-1 (activator protein-1) (reviewed in Angel and Karin, 1991) . While c-Jun represses the transcriptional activity of the AR-related glucocorticoid receptor (GR) (Schule et al., 1990) , as well as other nuclear receptors (reviewed in Pfahl, 1993) , it strongly potentiates ARmediated transcription (Shemshedini et al., 1992; Bubulya et al., 1996) . Several studies from our lab have characterized this coactivator function of c-Jun on AR (Bubulya et al., 1996 (Bubulya et al., , 2000 (Bubulya et al., , 2001 Tillman et al., 1998; Wise et al., 1998) . Perhaps the most intereting finding is that c-Jun's function as coactivator can be separated from that of a transactivator, as a transactivationdeficient mutant, c-Jun(Ala63/73), is still active in coactivation (Wise et al., 1998) . Moreover, whereas c-Fos strongly stimulates c-Jun's transactivation properties, it is equally able to repress its coactivation of AR (Tillman et al., 1998) . These results together strongly suggest that the transactivation and coactivation functions of c-Jun are distinct and thus may operate via different mechanisms. More recently, we have published that c-Jun can mediate AR N-to-C interaction and thereby enhance DNA binding (Bubulya et al., 2001) , an ability that is also observed with other AR coactivators, including SRC-1, TIF2, and CBP (Ikonen et al., 1997) .
To study the physiological relevance of c-Jun's coactivation of AR transactivation, we have generated stable LNCaP cells expressing different levels of c-Jun. Our data show that overexpression of the c-Jun mutant cJun(Ala63/73) leads to enhanced androgen-regulated AR transactivation, gene expression, and cell proliferation, whereas in the cells overexpressing antisense-c-Jun the effects are opposite. Importantly, short interference RNA (siRNA)-mediated downregulation of c-Jun in androgen-independent LNCaP cells also has a negative effect on their growth, strongly suggesting that c-Jun coactivation of AR is important in both the androgenresponsive and -unresponsive stages of prostate cancer. Finally, overexpression of wild-type c-Jun in LNCaP cells is antiproliferative, suggesting that high c-Jun transactivation reduces the growth of prostate cancer cells.
Results
Exogenous c-Jun enhances the transcriptional activity of endogenous AR in LNCaP cells Our previous data suggesting that c-Jun can act as an AR coactivator prompted us to investigate a possible regulatory role for c-Jun on the endogenous AR in LNCaP cells. Transient transfection experiments showed that c-Jun has the same positive effect on endogenous AR in LNCaP cells that has been seen on exogenous AR in other mammalian cells (Figure 1a) . In addition, a transactivation-deficient mutant of c-Jun, c-Jun(Ala63/73) (Wise et al., 1998) , was fully able to coactivate the endogenous AR in LNCaP cells Figure 1 c-Jun enhances, whereas antisense c-Jun represses, androgen-dependent AR transactivation in LNCaP cells. LNCaP cells were transfected with 2 mg MMTV-CAT or 2 mg TRE-tk-CAT and 1 or 5 mg c-Jun (a), c-Jun(Ala63/73) (b), or antisense c-Jun (c), as indicated. DHT (100 nM) was used as indicated. In all cases, the cells were grown in the absence (À) or presence ( þ ) of 100 nM DHT. All CAT activities are relative to the activity of the first condition, which was transfection of an empty expression plasmid, and this activity was set to 1. (Figure 3a) . Also note that the c-Jun(Ala63/73) lines have little activity on an AP-1-responsive reporter, whereas as expected, the antisense c-Jun cells have greatly reduced AP-1 activity (Figure 3b ). Western blot analysis showed that M37 cells have elevated c-Jun protein levels, whereas AJ81 cells have no detectable c-Jun (Figure 3c ). c-Jun is phosphorylated by JNK (Jun N-terminal kinase) at serines 63 and 73, which is necessary for its transactivation function (Smeal et al., 1991) but not its coactivation of AR (Wise et al., 1998) .
To determine the phosphorylation state of c-Jun in our stable LNCaP cell lines, Western blotting was performed using an anti-phospho-Ser63-c-Jun antibody. As shown in Figure 3d , the AJ81 cells have barely detectable levels of phosphorylated c-Jun. In contrast, J63 cells express high amounts of phosphorylated c-Jun ( Figure 3d ). As expected, M37 cells have significantly less phosphorylated c-Jun than do J63 cells, even though the total c-Jun expression levels are similar in these two cell lines (Figure 3d ). Importantly, these stably transfected LNCaP cells express AR protein to levels comparable to what is expressed in C14 cells (Figure 3e ), demonstrating that changes in endogenous c-Jun do not significantly alter the expression or stability of AR protein. were selected on neomycin-containing medium and screened for DHT-dependent transactivation by transiently transfecting 1 mg MMTV-CAT. 100 nM DHT was used to activate the AR in all cases. Note that the C14 line represents a stable transfection with the empty pCI-Neo vector. All activities are relative to the activity of either (a and b) untransfected LNCaP cells or (c) C14 cells, and this activity was set to 1.
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While the above experiments (see Figure 3a ) demonstrate that modulation of endogenous c-Jun levels in LNCaP cells affects AR transactivation of a transiently transfected reporter plasmid, they do not monitor changes in endogenous gene expression. To address this, we performed Northern blot, reverse transcriptasepolymerase chain reaction (RT-PCR), and Western blot analyses with RNA or proteins extracted from the stable cell lines to measure the expression of PSA and hKLK2. These two androgen-regulated genes are known to be upregulated in both proliferating LNCaP cells and prostate cancer (Gleave et al., 1992; Murtha et al., 1993) . As shown in Figure 4a and b, dihydrotestosterone (DHT) induced the expression of both PSA and hKLK2 in LNCaP cell lines. The same DHT induction was observed on prostate-specific antigen (PSA) protein levels ( Figure 4c ). Importantly, the expressions of hKLK2 mRNA and PSA mRNA and protein are significantly higher in M37 cells than in C14 cells . In contrast, the AJ81 cells, which have significantly reduced AR activity, yielded no detectable DHT induction of PSA mRNA ( Figure 4b ) and protein ( Figure 4c ). To determine if the expression of other androgenregulated genes may be altered in the stable LNCaP lines, we studied transmembrane protease serine 2 (TMPRSS2), a known androgen-regulated gene (Lin et al., 1999) . Like PSA and hKLK2, TMPRSS2 is overexpressed in prostate cancer cells (Lin et al., 1999) and in a majority of prostate cancer patients (Vaarala et al., 2001) . Recently, this gene was reported to undergo translocation with two ETs oncogenes in prostate cancer (Tomlins et al., 2005) . Both Northern blot ( Figure 4a ) and RT-PCR analyses ( Figure 4d ) showed that DHT induced the expression of TMPRSS2 mRNA in our LNCaP stable lines, consistent with previous reports (Lin et al., 1999) . Importantly, DHT-induced expression of TMPRSS2 is increased in M37 cells ( Figure 4a ) and significantly decreased in AJ6 cells (Figure 4d ). Northern blot analysis has shown two TMPRSS2 transcripts, one B3.8 kb and the other B2.0 kb (Paoloni-Giacobino et al., 1997). Our data demonstate that both transcripts are induced by DHT in LNCaP cells (Figure 4a ). Interestingly, the RT-PCR reactions yielded two different-sized products and showed that only the lower product is DHT induced (Figure 4d ). It is unclear whether these two PCR products reflect the two transcripts observed on the Northern blot ( Figure 4a ). These results, together with the PSA and hKLK2 data, clearly demonstrate that altering the endogenous levels of c-Jun in LNCaP cells results in changes in androgenregulated gene expression, arguing for a biological role for c-Jun in AR activity in LNCaP cells.
c-Jun coactivation mediates and transactivation inhibits androgen-dependent proliferation of LNCaP cells
To determine if this altered AR transcriptional activity affects a biological function of AR, androgen-dependent cellular proliferation was measured. However, first, the conditions for cellular proliferation were optimized as androgens have both stimulatory and inhibitory effects on LNCaP proliferation (Horoszewicz et al., 1983; Lee et al., 1995) , depending on the concentration of the steroid hormone and culture medium conditions. Therefore, the growth properties of LNCaP cells were studied LNCaP cells grown for 6 days in medium containing low FBS (2%) extracted with dextran-coated charcoal (DCC) exhibited a dose-dependent increase in cell number with increasing concentration of DHT (from 0.1 to 100 nM) (Figure 5a ), in agreement with earlier results (Horoszewicz et al., 1983) , whereas those grown in the presence of 10% FBS showed a slight decrease (S Chen and L Shemshedini, unpublished results). To study the effect of 100 nM DHT on proliferation, LNCaP cells were grown in the presence of either carrier (ethanol) or DHT for 1, 2, and 6 days in medium with 2 or 10% FBS.
As expected, cells grown in 2% FBS medium showed a DHT-dependent increase in cell number with increasing time (Figure 5b ), whereas those grown in 10% FBScontaining medium showed a decrease in proliferation (S Chen and L Shemshedini, unpublished results). To confirm that our growth conditions allowed us to observe androgen-induced proliferation, we compared the effect of DHT to that of R1881, a synthetic analog of DHT that is more stable than DHT (Schuurmans et al., 1988) . As shown in Figure 5c , 1 nM R1881 is sufficient to induce optimal proliferation of LNCaP cells, as reported previously (Song et al., 2004) . Importantly, 1 nM R1881 is as active, if not slightly c-Jun enhances androgen-induced proliferation S-Y Chen et al more active, on proliferation as is 100 nM DHT (Figure 5c ). To determine if this difference between DHT and R1881 could be explained by AR protein stability, which is strongly stimulated by androgens (Yeap et al., 1999) , AR protein levels were measured by Western blotting. DHT had a significant stabilizing effect on AR protein only at a concentration of 100 nM, whereas R1881 was equally effective from 1 to 100 nM (Figure 5d ). These results demonstrate that, under our culture conditions, 100 nM DHT has the same effect as 1 nM R1881 on LNCaP cellular proliferation. Thus, the above growth conditions (2% FBS medium and 100 nM DHT) were used to compare the proliferation of the stable LNCaP cell lines. M37 and M26 cells had enhanced DHT-dependent proliferation, compared to the control C14 cells (Figure 6a ). In contrast, the AJ6 and AJ81 cells lost most of their proliferative response to DHT (Figure 6b) . Surprisingly, cell overexpressing wild-type c-Jun protein grew as poorly as the antisense cJun-expressing cells (Figure 6c ). Importantly, none of the stable cell lines differed significantly from C14 cells in growth under DHT-minus conditions, demonstrating that overexpression of wild-type or mutant c-Jun or under-expression of endogenous c-Jun did not affect the inherent growth rate of the cells. Together, these results strongly suggest that endogenous c-Jun plays an important role in DHT-induced proliferation of LNCaP cells and the coactivation function of exogenously expressed c-Jun is proproliferative and its transactivation function is antiproliferative. Note that AR expression is not significantly changed in these stable LNCaP cell lines (see Figure 3e ; C Cai and L Shemshedini, unpublished results).
c-Jun mediates the proliferation of androgen-independent LNCaP cells To determine the importance of c-Jun in androgenindependent LNCaP cells, we studied androgen-independent LNCaP cells that were established through continuous passage in culture (Lin et al., 1998; Igawa et al., 2002) . These cells, C81, closely mimic hormonerefractory prostate cancer and thus proliferate in an androgen-unresponsive manner, whereas C33 are the parental androgen-dependent cells (Igawa et al., 2002) . c-Jun enhances androgen-induced proliferation S-Y Chen et al stability (Yeap et al., 1999) . RT-PCR analysis was used to demonstrate that DHT can induce the expression of PSA and TMPRSS2 mRNA in both C33 and, more weakly, C81 cells (Figure 7d ). When AR transactivation was measured using MMTV-CAT (Bubulya et al., 1996) , both wild-type c-Jun and c-Jun(Ala63/73) were able to stimulate AR transcriptional activity (Figure 7e ), but with a lower capacity than what was observed in androgen-dependent LNCaP cells (see Figure 1 ). These results demonstrate that c-Jun coactivation of AR can occur in both androgen-dependent and androgenindependent LNCaP cells.
In view of the importance of c-Jun in the growth of androgen-independent LNCaP cells, we were interested in exploring a possible proliferative role for c-Jun in androgen-independent cells. We utilized siRNAmediated repression of c-Jun, which was effective on both c-Jun mRNA (Figure 8a ) and protein (Figure 8b ) levels. These siRNA-transfected cells were then studied for growth, which expectedly is androgen-independent. As shown in Figure 8c , the androgen-independent proliferation of C81 cells is dramatically reduced by c-Jun siRNA treatment, as compared to control siRNA. As the siRNA pool used above consisted of two distinct siRNAs targeting different regions of c-Jun, we tested each siRNA separately to ensure the specificity of the approach. As shown in Figure 8d , both siRNAs are able to inhibit c-Jun expression but they differ in magnitude. This difference in magnitude on c-Jun expression correlated directly with the siRNA effectiveness on cellular proliferation (Figure 8e ). Collectively, these data illustrate an important role for endogenous c-Jun in the androgen-independent growth of LNCaP cells.
c-Jun can coactivate AR in PC-3 cells
The data described above demonstrate that c-Jun can enhance AR transactivation in both androgen-dependent and androgen-independent LNCaP cells. PC-3 cells were used to determine if c-Jun coactivation of AR can occur in androgen-independent prostate cancer cells that do not express endogenous AR. These cells were stably transfected with AR, giving rise to A103 cells (Salas et al., 2004) , which express AR protein levels comparable to LNCaP cells (S Chen and L Shemshedini, unpublished results) and thus exhibit androgen-induced AR transactivation (Figure 9a ). Interestingly, both wildtype c-Jun and c-Jun(Ala63/73) can enhance AR transactivation in A103 cells (Figure 9a) , showing that c-Jun coactivation of AR can occur in different prostate cancer cell lines. To determine if the endogenous c-Jun is involved in A103 cellular proliferation, this c-Jun expression was repressed by siRNA ( Figure 9b ). A103 cellular proliferation is weakly but reproducibly inhibited by DHT (Figure 9c ), as it has been shown for other AR-expressing PC-3 cells (Heisler et al., 1997) . More interestingly, transfection with c-Jun siRNA markedly reduced A103 proliferation (Figure 9c ), suggesting an endogenous role for c-Jun in PC-3 cellular proliferation.
c-Jun expression is elevated in prostate cancer tissues Collectively, our cellular proliferation data above strongly suggest that c-Jun coactivation of AR is involved in the two distinct growth stages of LNCaP cells: androgen-dependent and androgen-independent. This finding implicates the possible involvement of c-Jun in androgen-refractory prostate cancer, the lethal form of the disease. Support for a possible c-Jun involvement in prostate carcinogenesis depends on demonstrating its expression in human tumor tissues. We have used RT-PCR to measure c-Jun expression in several prostate cancer cell lines and prostate tissues. As shown in Figure  10a , c-Jun mRNA is expressed similarly in LNCaP and 
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PC-3 cells, without a significant effect by DHT treatment. The tissues studied were purchased from the Cooperative Human Tissue Network (CHTN), which identifies these tissues as normal, benign prostatic hyperplasia (BPH), or malignant prostate cancer (MPC). Interestingly, c-Jun mRNA is only detected in our two MPC and one BPH samples (Figure 10b ). Importantly, these three tissues also express elevated levels of PSA, AR, and EZH2 (Varambally et al., 2002) mRNAs (Figure 10b ).
Discussion
The c-Jun proto-oncoprotein can activate transcription through at least two mechanisms: transactivation and coactivation. The transactivation properties of c-Jun are well understood, having clearly demonstrated that this protein is found together with c-Fos in AP-1, which is able to transcriptionally regulate the expression of genes important for cell division (reviewed in Shaulian and Karin, 2001) . In contrast, c-Jun's coactivation function is less well understood. This c-Jun action appears to be limited to only a few transcriptional activators, including AR and the three ETS transcription factors ERM (Nakae et al., 1995) , PU.1 (Behre et al., 1999) , and ETV1 (C Cai and L Shemshedini, unpublished results).
Interestingly, at least with regard to AR (Wise et al., 1998) , PU.1 (Behre et al., 1999) , and ETV1 (C Cai and L Shemshedini, unpublished results), c-Jun's function as a coactivator is separable from its transactivation function, as the c-Jun(Ala63/73) mutant is deficient in transactivation but fully active in coactivation. This separation of AR coactivation from AP-1 transactivation has been demonstrated in a variety of cell lines, including Cos (Bubulya et al., 2001) , androgen-dependent and -independent LNCaP, and AR-expressing PC-3 cells. In addition, c-Fos strongly stimulates cJun's transactivation properties but represses its coactivation of AR (Tillman et al., 1998) . These results together strongly suggest that the transactivation and coactivation functions of c-Jun are distinct and thus may operate via different mechanisms. In this paper, we provide evidence that, for prostate cancer cells, c-Jun coactivation of AR is proliferative, whereas, surprisingly, c-Jun transactivation is antiproliferative. LNCaP is a lymph node-derived prostate cancer cell line that expresses AR, c-Jun, and c-Fos (Henttu and Vihko, 1998) . Because this cell line has many of the same androgen-regulated properties that are found in androgen-sensitive, early-stage prostate cancer (reviewed in Jester, 1999), LNCaP cells are used as a model for studying androgen-sensitive prostate cancer. These properties include androgen-induced cellular proliferation and gene expression. LNCaP cells were, therefore, c-Jun enhances androgen-induced proliferation S-Y Chen et al used in this study to determine the importance of c-Jun in AR-dependent proliferation of prostate cancer cells, an important biological function for AR in prostate cancer. Stable LNCaP cells were generated that expressed different levels of either wild-type c-Jun or c-Jun(Ala63/73) protein, or antisense c-Jun. As expected, expression of either c-Jun protein resulted in enhanced AR transactivation of an androgen-regulated reporter gene and, more importantly, known endogenous androgen-regulated genes. In contrast, expression of antisense c-Jun had a negative effect. These transcription results are completely consistent with our earlier data using transient transfection experiments (Bubulya et al., 1996 (Bubulya et al., , 2000 (Bubulya et al., , 2001 Tillman et al., 1998; Wise et al., 1998) and strongly suggest that endogenous levels of c-Jun in LNCaP cells are both required and limiting for androgen-regulated gene expression. Although it is not known how widespread the involvement of c-Jun coactivation on the expression of androgen-regulated genes is, it is important to note that all three androgen target genes analysed in this study appear to be regulated by c-Jun coactivation.
One important biological consequence of androgenregulated gene expression is induction of prostate cancer cell proliferation, which is clearly demonstrated by LNCaP cells. Indeed, our data with the stable LNCaP cell lines implicate a role for c-Jun coactivation in this property. In the cell lines expressing c-Jun(Ala63/73) protein or antisense c-Jun, androgen-induced cellular proliferation is directly proportional to the magnitude of AR transcriptional activity. These results demonstrate that alteration of AR transcriptional activity in response to changes in endogenous c-Jun levels leads to changes in cellular proliferation. Our data with the antisense c-Jun-expressing cells show that reducing endogenous In all cases, the cells were grown in the absence (À) or presence ( þ ) of 100 nM DHT. All luciferase activities are relative to the activity of the first condition, which was transfection of an empty expression plasmid, and this was set to 1. A103 cells were transfected with a c-Jun siRNA pool, or control siRNA, and subjected to (b) Western blotting or (c) proliferation using cells grown for 0, 2, and 4 days in the absence (À) or presence ( þ ) of 100 nM DHT. The bar graphs represent three independent experiments plus standard deviations. Additional evidence comes from the cell lines expressing c-Jun(Ala63/73), which exhibit significantly elevated growth of LNCaP cells in the presence of DHT, but no effect in its absence. This c-Jun mutant protein is fully able to coactivate androgen-dependent transactivation, but is deficient in AP-1 transactivation (Wise et al., 1998) . It has been previously reported that c-Jun can mediate G1 cell-cycle progression of fibroblasts independent of phosphorylation of its serines 63 and 73 (Wisdom et al., 1999) . Therefore, it is possible that the cJun mutant may be having a similar effect in LNCaP cells. Nevertheless, our finding that the c-Jun(Ala63/73) mutant affects only androgen-dependent proliferation strongly suggests that this effect is mediated via AR coactivation.
In It is also possible that the reduced cellular growth in c-Junexpressing prostate cancer cells is owing to increased apoptosis, since c-Jun transactivation is known to induce apoptosis in neurons, lymphocytes, and hepatocytes (reviewed in Ameyar et al., 2003) . Future work will determine if overexpression of c-Jun in LNCaP cells leads to decreased cell-cycle progression and/or increased apoptosis.
Whatever the mechanism of action of c-Jun transactivation is in LNCaP cells, our data strongly suggest that c-Jun coactivation strongly enhances AR-dependent gene expression and androgen-induced cellular proliferation. Additionally and perhaps more importantly, endogenous c-Jun is required for the proliferation of androgen-independent LNCaP cells. Utilizing LNCaP cells that were cultured to grow independent of androgens and thereby mimic the hormone-refractory stage of prostate cancer (Lin et al., 1998; Igawa et al., 2002) , we have been able to block the growth of these cells, in either the absence or presence of androgens, by siRNA-mediated diminishing of endogenous c-Jun expression. As these cells exhibit c-Jun coactivation of AR-dependent transcription and we have evidence that their proliferation is dependent on AR-regulated gene expression (C Cai and L Shemshedini, unpublished results), it is likely that the proliferative role of endogenous c-Jun in androgen-independent LNCaP cells is mediated via its coactivation function on AR, irrespective of whether androgen is present or not. Future studies can determine if c-Jun coactivation of AR regulates the same proproliferation genes in androgen-dependent and -independent LNCaP cells.
Materials and methods

Plasmids
To make c-Jun/pCI-Neo, c-Jun/pSG5 (Bubulya et al., 2001) was digested with BsaAI and XbaI, and the restriction fragment was filled in with DNA polymerase klenow fragment. This fragment was then inserted into EcoRV-digested pTRE2 vector (Clontech, Mountain View, CA, USA) to get c-Jun/ pTRE2. c-Jun/pTRE2 was digested with SalI and XbaI and inserted into pCI-Neo (Promega, Madison, WI, USA) digested with XhoI and XbaI, yielding c-Jun/pCI-Neo.
To make antisense-c-Jun/pCI-Neo, c-Jun/pTRE2 was digested by NheI and XbaI and inserted into pCI-Neo in reverse orientation.
To make c-Jun(Ala63/73)/pCI-Neo, c-Jun(Ala63/73)/RSV (Bubulya et al., 2001) was digested with BsaAI and StyI and filled in with DNA polymerase klenow fragment. This fragment was then inserted into EcoRV-digested pTRE2 to get c-Jun(Ala63/73)/pTRE2. c-Jun(Ala63/73)/pTRE2 was digested with SalI and XbaI and inserted into pCI-Neo digested with XhoI and XbaI, yielding c-Jun(Ala63/73)/pCI-Neo.
The reporter plasmids MMTV-CAT, TRE-tk-CAT, and PSA-Luc have been previously described (Bubulya et al., 1996; Shenk et al., 2001) . Transfection efficiency was standardized by measuring the b-galactosidase activity, originating from the cotransfected plasmid pCH110.
Generation of stable cell lines
LNCaP cells were grown to 60-70% confluence in RPMI 1640 complete medium (Sigma, St Louis, MD, USA) containing 10%FBS (from Hyclone, Logan, UT, USA). Then, the medium was changed to DMEM complete medium (Sigma) for overnight incubation. Cells were transfected with 2 mg each of pCI-Neo vector (negative control from Promega), c-Jun/ pCI-Neo, antisense c-Jun/pCI-Neo, or c-Jun(Ala63/73)/pCINeo, using calcium phosphate precipitation (CaPO 4 ) method (Bubulya et al., 2001) . At 24 h after transfection, the cells were again incubated in RPMI 1640 complete medium. After 48 h, LNCaP cells were selected in RPMI 1640 complete medium containing 0.9 mg/ml neomycin. The medium was refreshed every 4 days until single colonies appeared. The colonies were screened by CAT assay of transiently transfected cells with MMTV-CAT. The generation of A103 cells, which stably express AR, has been previously described (Salas et al., 2004) .
Transient transfections and reporter gene assays
Transient transfections were carried out using the CaPO 4 method as described above in LNCaP cells and stable lines of LNCaP cells, in which case the medium contained 0.1 mg/ml neomycin. A103 cells were transfected using FuGENE 6 (Roche, Basel, Switzerland). Cells were incubated with or without 100 nM DHT for 24 h, after which whole-cell extracts were prepared and then subjected to CAT or luciferase assays as described (Bubulya et al., 1996; Shenk et al., 2001) . CAT or luciferase assays were standardized according to the measured b-galactosidase activity as previously described (Bubulya et al., 1996) . For all transfections, we used different amounts of expression plasmid, 1 mg reporter plasmid (MMTV-CAT, TRE-tk-CAT, or PSA-Luc), 2 mg pCH110, and enough pTL1 to bring the final plasmid amount to 10 mg per dish. For all transfections, empty vector (empty expression plasmid and/or promoterless reporter plasmid) was used to ensure equal amounts of each kind of vector. CAT assay results were quantified using the BioRad Molecular Imager FX of at least three repeats for each transfection. Thus, each CAT assay or luciferase value represents the average of three to four repeats plus standard deviation.
siRNA transfection C33 or C81 LNCaP cells were grown in RPM1 1640 medium with 0.05 mg/ml gentamicin (Gibco, Carlsbad, CA, USA) and supplemented with 5% FBS. A103 cells were grown in F12K medium (Sigma) supplemented with 5% FBS. Cells were transfected with the c-Jun siRNA pool sc-44201 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), either of two c-Jun siRNAs (sc-44201A or sc-44201B, Santa Cruz Biotechnology) or negative control siRNA 4611G (Ambion, Austin, TX, USA). The X-tremeGENE siRNA transfection reagent was used following the prescribed protocol (Roche). The final siRNA concentration was 25 or 50 nM for each transfection.
Cell proliferation assay 50 000 cells were grown in a 24-well-plate with 500 ml RPMI 1640 medium (LNCaP cells) or F12K medium (A103 cells) containing 2% DCC-stripped FBS. After a 2-day incubation, either ethanol or 100 nM DHT was added into the wells. Then, the MTT (3-[4,5]dimethylthiazol-2,5-diphenyltetrazolium bromide) (Sigma) assay was performed after 0-6 days (LNCaP cells) or 0-4 days (A103 cells) of incubation following the manufacturer's protocol. The neomycin concentration was 0.1 mg/ml for the LNCaP stable cell lines and 0.2 mg/ml for A103 cells.
Western blot analysis
To prepare cell extracts for Western blot analysis, cells were boiled for 5-10 min in sodium dodecyl sulfate (SDS)-sample buffer (63 mM Tris, pH 6.8; 20% glycerol; 2% SDS; 5% b-mercaptoethanol). Proteins were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and then electrotransferred onto nitrocellulose. After blocking with nonfat dry milk, the nitrocellulose blots were probed with the anti-c-Jun antibody sc-45 (Santa Cruz Biotechnology), anti-phosphoSer63 c-Jun antibody sc-822 (Santa Cruz Biotechnology), the anti-AR antibody PA1-110 (Affinity BioReagents, Golden, CO, USA), the anti-PSA antibody sc-7638 (Santa Cruz Biotechnology), or the anti-b-actin antibody ab6276 (Abcam, Cambridge, MA, USA) as a control for protein loading. The blots were developed using the chemiluminescence detection kit from Amersham, Piscataway,New Jersey, USA.
Northern blot analysis RNA was isolated using the TRIZOL Reagent (Invitrogen, Carlsbad, CA, USA) as recommended by the manufacturer and run on an agarose-formaldehyde gel. In total, 20 mg of total RNA was used. GAPDH was used as a control.
Semiquantitative RT-PCR analysis RNA was isolated using the TRIZOL Reagent and then subjected to reverse transcription using M-MLV Reverse Transcriptase (Fisher) following the manufacturer's protocol. The cDNA product was used for PCR using the PCR Master Mix (Promega). The PCR products were separated by agarose gel-electrophoresis and stained with ethidium bromide. The following PCR primers were used: c-Jun 
